Le Lézard
Classified in: Health, Science and technology
Subject: INVESTMENT OPINION

Portzamparc Groupe BNP Paribas Initiates the Coverage of Median Technologies with a "Strong Buy" Recommendation


Regulatory News:

Median Technologies (Euronext Growth - ALMDT) announces today the publication of an initiation report by Portzamparc Groupe BNP Paribas, a French leading group covering brokerage for Individual and institutional investors, and financial operations for corporate and Institutional clients.

In the initiation report published on July 20, 2023, Portzamparc Groupe BNP Paribas initiates the coverage of the stock with a Strong Buy recommendation.

About Portzamparc Groupe BNP Paribas: Portzamparc's offering is built around three areas of expertise: support for private and institutional investors on the stock market, with a transaction volume of nearly ?9 billion; third-party asset management, with ?4 billion in assets under management; and market operations for SMEs/ETIs, with undisputed leadership in IPOs. From IPOs to financial analysis, Portzamparc's experience and reputation make it the benchmark for mid-cap companies.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered imaging platform for the development of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (Paris). FR0011049824? ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com


These press releases may also interest you

at 00:00
Author Kory L. Wilson and his family have experienced the benefits of information he shares in Home Remedies: A Guidebook To Breaking Away From Big Pharma ($15.99, paperback, 9781662896668; $6.99, e-book, 9781662896675). For years, I have collected...

15 mai 2024
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...

15 mai 2024
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...

15 mai 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...

15 mai 2024
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...

15 mai 2024
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...



News published on and distributed by: